<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medbio</journal-id><journal-title-group><journal-title xml:lang="ru">Медико-биологические проблемы жизнедеятельности</journal-title><trans-title-group xml:lang="en"><trans-title>Medical and Biological Problems of Life Activity</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2074-2088</issn><publisher><publisher-name>Республиканский научно-практический центр радиационной медицины и экологии человека</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.58708/2074-2088.2024-1(31)-118-123</article-id><article-id custom-type="elpub" pub-id-type="custom">medbio-348</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКАЯ МЕДИЦИНА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL MEDICINE</subject></subj-group></article-categories><title-group><article-title>Сахарный диабет 2 типа и ассоциированные с ним метаболические нарушения, распространенность среди трудоспособного населения</article-title><trans-title-group xml:lang="en"><trans-title>Type 2 diabetes mellitus and associated metabolic disorders, prevalence within the working-age population</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5722-6946</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Савастеева</surname><given-names>И. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Savasteeva</surname><given-names>I. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>г. Гомель</p></bio><email xlink:type="simple">savastteeva69@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8879-5079</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ярец</surname><given-names>Ю. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Yarets</surname><given-names>Yu. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>г. Гомель</p></bio><email xlink:type="simple">gr-rcrm@tut.by</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8478-6316</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бронская</surname><given-names>К. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Bronskaya</surname><given-names>K. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>г. Гомель</p></bio><email xlink:type="simple">ks_bronski@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0004-8610-7040</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кандера</surname><given-names>Ю. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Kandzera</surname><given-names>Yu. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>г. Гомель</p></bio><email xlink:type="simple">orgmetod@mail.gomel.by</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>ГУ «РНПЦ радиационной медицины и экологии человека»</institution><country>Belarus</country></aff><aff xml:lang="ru" id="aff-2"><institution>УЗ «Гомельская областная клиническая больница»</institution><country>Belarus</country></aff><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>25</day><month>03</month><year>2024</year></pub-date><volume>0</volume><issue>1</issue><fpage>118</fpage><lpage>123</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Савастеева И.Г., Ярец Ю.И., Бронская К.В., Кандера Ю.С., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Савастеева И.Г., Ярец Ю.И., Бронская К.В., Кандера Ю.С.</copyright-holder><copyright-holder xml:lang="en">Savasteeva I.G., Yarets Y.I., Bronskaya K.V., Kandzera Y.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://medbio.ejournal.by/jour/article/view/348">https://medbio.ejournal.by/jour/article/view/348</self-uri><abstract><p>За 11-ти летний период наблюдения СД 2 типа (Е11) в единичных случаях регистрировался в возрасте 25-29 лет на фоне опережающей первичной заболеваемости ожирением, связанным с избыточным поступлением энергетических ресурсов (Е66). Регистрировалась низкая заболеваемость различными формами нарушений толерантности к глюкозе (R73). Показатель заболеваемости дислипидемией (Е78) был сопоставим с уровнем заболеваемости СД 2 типа.</p><p>Были определены предикторы и риск развития СД 2 типа более чем у 1,5 тыс. здоровых респондентов. Более 80,0% респондентов имели низкий 10-ти летний риск развития СД 2 типа. Однако проведенный анализ свидетельствовал о негативном воздействии атерогенных липидов на уровни гликирования гемоглобина, вероятном влиянии на развитие инсулинорезистентности, росте риска предиабета и клинико-лабораторной манифестации СД 2 типа у пациентов с высоким 10-ти летним риском. В группе здоровых трудоспособных респондентов ОР высокий риск/низкий риск (по Findrisk) предиабета составил 2,58 (1,58; 4,22) и был статистически значим.</p><p>Анализ факторов, оказывающих влияние на риск развития СД 2 типа, показал высокую распространенность как корректируемых, так и не корректируемых факторов риска во всех группах трудоспособного населения Республики Беларусь.</p><p>При планировании мероприятий по первичной профилактике неинфекционных заболеваний у населения необходимо основываться на результатах оценки и возможности снижения популяционных рисков. Оценка рисков позволяет выявлять и формировать группы наблюдения население, для которого возможно назначение профилактического лечения для коррекции метаболических нарушений.</p></abstract><trans-abstract xml:lang="en"><p>Over an 11-year observation period, type 2 diabetes mellitus (E11) was recorded in isolated cases at the age of 25-29 years against the preceding background of primary incidence of obesity associated with excess intake of energy resources (E66). A low incidence of various forms of impaired glucose tolerance was reported (R73). The incidence rate of dyslipidemia (E78) was comparable to the incidence rate of type 2 diabetes mellitus.</p><p>Predictors and risk of developing type 2 diabetes mellitus were determined in more than 1,5 thousand healthy respondents. More than 80,0% of respondents had a low 10-year risk of developing type 2 diabetes mellitus. However, the analysis indicated a negative effect of atherogenic lipids on the levels of hemoglobin glycation, a probable effect on the development of insulin resistance, an increased risk of prediabetes and clinical and laboratory manifestations of type 2 diabetes mellitus in patients with a high 10-year risk. In the group of healthy workingage respondents, the RR high risk/low risk (according to Findrisk) of prediabetes was 2,58 (1,58; 4,22) and was statistically significant.</p><p>Analysis of factors influencing the risk of developing type 2 diabetes mellitus showed a high prevalence of both modifiable and non-modifiable risk factors in all groups of the workingage population of the Republic of Belarus.</p><p>When planning activities for the primary prevention of non-communicable diseases in the population, it is necessary to be based on the results of the assessment and the feasibility of reducing population risks. Risk assessment makes it possible to identify and form followup groups of population for which it is possible to administer preventive treatment to correct metabolic disorders.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>сахарный диабет 2 типа</kwd><kwd>факторы риска</kwd><kwd>риск развития сахарного диабета 2 типа</kwd></kwd-group><kwd-group xml:lang="en"><kwd>type 2 diabetes mellitus</kwd><kwd>risk factors</kwd><kwd>risk of developing type 2 diabetes mellitus</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Cardiovascular disease in Europe– epidemiological update / N. Townsend [et al.] // Eur Heart J . – 2015. – V. 36. – P. 2696-2705.</mixed-citation><mixed-citation xml:lang="en">Cardiovascular disease in Europe– epidemiological update / N. Townsend [et al.] // Eur Heart J . – 2015. – V. 36. – P. 2696-2705.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) // European Heart Journal. – 1 January 2020. – V. 41, Issue 1. – P. 111-188.</mixed-citation><mixed-citation xml:lang="en">2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) // European Heart Journal. – 1 January 2020. – V. 41, Issue 1. – P. 111-188.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate and hyperglycaemia. Report of a WHO/IDF consultation. Доступно по: http://www.who.int/diabetes/publications/diagnosis_diabetes2006/en/ (June 14 2019).</mixed-citation><mixed-citation xml:lang="en">World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate and hyperglycaemia. Report of a WHO/IDF consultation. Доступно по: http://www.who.int/diabetes/publications/diagnosis_diabetes2006/en/ (June 14 2019).</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">American Diabetes Association ADA. Standards of medical care in diabetes-2020. Diabetes Care 2020.</mixed-citation><mixed-citation xml:lang="en">American Diabetes Association ADA. Standards of medical care in diabetes-2020. Diabetes Care 2020.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">2019 ESC Guidelines on diabetes, prediabetes, and cardiovascular diseases developed in collaboration with the EASD // European Heart Journal. – 2019. – V.00. P.1-69 ESC GUIDELINES.</mixed-citation><mixed-citation xml:lang="en">2019 ESC Guidelines on diabetes, prediabetes, and cardiovascular diseases developed in collaboration with the EASD // European Heart Journal. – 2019. – V.00. P.1-69 ESC GUIDELINES.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">European Practical and Patient-Centred Guidelines for Adult Obesity Management in Primary Care // Obes Facts. – 2019. – V.12. – P.40-66. Published online: January 23, 2019.</mixed-citation><mixed-citation xml:lang="en">European Practical and Patient-Centred Guidelines for Adult Obesity Management in Primary Care // Obes Facts. – 2019. – V.12. – P.40-66. Published online: January 23, 2019.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
